MedTrace Logo

PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care

NCT07711821 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-07-17

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether the use of NT-proBNP testing and point-of-care ultrasound (POCUS) can improve the diagnosis and management of heart failure in adults aged 50 years or older with suspected heart failure or cardiovascular risk factors in primary care settings.

The main questions it aims to answer are:

* Does the use of NT-proBNP and/or POCUS increase the rate of new heart failure diagnoses compared with standard care?
* Does this approach support earlier initiation of guideline-directed medical therapy and improve patients' quality of life?

Researchers will compare standard care alone with standard care combined with NT-proBNP testing, POCUS, or both, to assess their impact on diagnosis and management of heart failure.

Participants will:

* Be randomly assigned to one of four groups (standard care, NT-proBNP, POCUS, or both).
* Undergo clinical evaluation for heart failure according to their assigned group.
* Be followed for 12 months with periodic assessments of quality of life and treatment adherence.

Conditions

Interventions

DIAGNOSTIC_TEST

NT-proBNP testing

Measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in blood as part of the diagnostic evaluation for suspected heart failure in primary care.

DEVICE

Cardiac Point-of-Care Ultrasound (POCUS)

Cardiac point-of-care ultrasound performed by trained primary care physicians to assess cardiac structure and function as part of the diagnostic evaluation for suspected heart failure.

OTHER

standard of care

Usual clinical evaluation and management in primary care according to standard practice, without additional diagnostic interventions specified in the study.

Sponsors & Collaborators

  • Universidade do Porto

    lead OTHER

Principal Investigators

  • Jonathan dos Santos · Aveiro University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-23
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07711821 on ClinicalTrials.gov